| scholarly article | Q13442814 |
| P50 | author | Holden T. Maecker | Q93173386 |
| P2093 | author name string | David J Glass | |
| Giuseppe Del Giudice | |||
| John Kovarik | |||
| Jens Praestgaard | |||
| Nicholas M Valiante | |||
| Lloyd B Klickstein | |||
| Simon Carson | |||
| Maria Lattanzi | |||
| Baisong Huang | |||
| Joan B Mannick | |||
| Michael A Lonetto | |||
| P2860 | cites work | Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses | Q37143494 |
| PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia | Q37337817 | ||
| The gracefully aging immune system | Q38107139 | ||
| The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine | Q43546829 | ||
| Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy | Q46623415 | ||
| Molecular analyses provide insight into mechanisms underlying sarcopenia and myofibre denervation in old skeletal muscles of mice. | Q51139758 | ||
| Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies | Q57591588 | ||
| Rapamycin fed late in life extends lifespan in genetically heterogeneous mice | Q24647805 | ||
| mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
| Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 | ||
| The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. | Q30354732 | ||
| Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data | Q33323274 | ||
| Preserving youth: does rapamycin deliver? | Q33605653 | ||
| mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells | Q33609242 | ||
| Late-life rapamycin treatment reverses age-related heart dysfunction. | Q33903651 | ||
| Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway | Q34137984 | ||
| Rapamycin slows aging in mice | Q34275079 | ||
| Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses | Q34565248 | ||
| NFATc1 regulates PD-1 expression upon T cell activation. | Q34597324 | ||
| Viral acute lower respiratory infections impair CD8+ T cells through PD-1 | Q36129102 | ||
| Antibody response to influenza vaccination in the elderly: a quantitative review | Q36280602 | ||
| P433 | issue | 268 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immune function | Q124683452 |
| P304 | page(s) | 268ra179 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | mTOR inhibition improves immune function in the elderly | |
| P478 | volume | 6 |
| Q47872250 | A Perfect sTORm: The Role of the Mammalian Target of Rapamycin (mTOR) in Cerebrovascular Dysfunction of Alzheimer's Disease: A Mini-Review |
| Q37263716 | A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve |
| Q92034859 | A novel rapamycin analog is highly selective for mTORC1 in vivo |
| Q50148782 | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects |
| Q55174539 | A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. |
| Q55387511 | A system to identify inhibitors of mTOR signaling using high-resolution growth analysis in Saccharomyces cerevisiae. |
| Q90389012 | A triple drug combination targeting components of the nutrient-sensing network maximizes longevity |
| Q38430701 | Advances in Therapeutic Approaches to Extend Healthspan: a perspective from the 2nd Scripps Symposium on the Biology of Aging |
| Q27318656 | Age-Dependent Cell Trafficking Defects in Draining Lymph Nodes Impair Adaptive Immunity and Control of West Nile Virus Infection |
| Q36614145 | Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions |
| Q38868206 | Ageing and obesity similarly impair antibody responses |
| Q92074835 | Agephagy - Adapting Autophagy for Health During Aging |
| Q39397591 | Aging and Caloric Restriction Research: A Biological Perspective With Translational Potential |
| Q43185647 | Aging interventions get human. |
| Q38946555 | Aging of the immune system: Focus on inflammation and vaccination |
| Q92494933 | Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis |
| Q34497857 | Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system |
| Q92512523 | An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice |
| Q59096646 | Anti-ageing pill pushed as bona fide drug |
| Q55364518 | Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). |
| Q38636645 | B Cell-Specific Biomarkers for Optimal Antibody Responses to Influenza Vaccination and Molecular Pathways That Reduce B Cell Function with Aging |
| Q38506851 | Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity |
| Q26777407 | Biochemical Genetic Pathways that Modulate Aging in Multiple Species |
| Q38741294 | Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment |
| Q90438674 | Calorie-Restriction-Induced Insulin Sensitivity Is Mediated by Adipose mTORC2 and Not Required for Lifespan Extension |
| Q38662550 | Can aging be 'drugged'? |
| Q57165494 | Cardiac ageing: extrinsic and intrinsic factors in cellular renewal and senescence |
| Q39246705 | Cellular Senescence: A Translational Perspective |
| Q35758129 | Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. |
| Q36245247 | Classifying aging as a disease in the context of ICD-11. |
| Q56892381 | Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity |
| Q47563994 | Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies |
| Q38815953 | Considerations for successful cancer immunotherapy in aged hosts |
| Q36169646 | Defective T Memory Cell Differentiation after Varicella Zoster Vaccination in Older Individuals |
| Q26766217 | Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic |
| Q38401015 | Developing vaccines for an aging population |
| Q60054020 | Disease or not, aging is easily treatable |
| Q36406255 | Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span |
| Q42388967 | Does Longer Lifespan Mean Longer Healthspan? |
| Q36414149 | Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program). |
| Q48147612 | Effects of rapamycin on growth hormone receptor knockout mice. |
| Q52596335 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. |
| Q58548409 | Emerging Interventions for the Elderly - The Promise of Regenerative Medicine |
| Q39291992 | Energetic interventions for healthspan and resiliency with aging |
| Q90726758 | Epigenetic Regulation of KL (Klotho) via H3K27me3 (Histone 3 Lysine [K] 27 Trimethylation) in Renal Tubule Cells |
| Q40202162 | Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. |
| Q59090300 | Facing up to the global challenges of ageing |
| Q39375320 | Factors affecting immune responses to the influenza vaccine |
| Q92577217 | Fasting and rapamycin: diabetes versus benevolent glucose intolerance |
| Q47140159 | Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging |
| Q49988904 | Find drugs that delay many diseases of old age. |
| Q26747742 | Finding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging Molecules |
| Q98177704 | From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment |
| Q91776870 | From discoveries in ageing research to therapeutics for healthy ageing |
| Q33829205 | From rapalogs to anti-aging formula |
| Q56881067 | Gene expression-based drug repurposing to target aging |
| Q97905883 | Genetics of extreme human longevity to guide drug discovery for healthy ageing |
| Q92671753 | Geroscience and the challenges of aging societies |
| Q26751200 | Geroscience approaches to increase healthspan and slow aging |
| Q37610218 | Gerosuppression by pan-mTOR inhibitors |
| Q49417693 | Harnessing the mTOR Pathway for Tuberculosis Treatment |
| Q26770924 | Healthy aging: The ultimate preventative medicine |
| Q58765738 | Horizons in the evolution of aging |
| Q38890854 | Host Resistance and Immune Aging. |
| Q39451386 | Human T cell immunosenescence and inflammation in aging |
| Q104800210 | Human monocyte-derived macrophage responses to M. tuberculosis differ by the host's tuberculosis, diabetes or obesity status, and are enhanced by rapamycin |
| Q61804657 | Identifying Potential Ageing-Modulating Drugs In Silico |
| Q91983062 | Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics |
| Q40604193 | Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor γδ T Cells. |
| Q93065024 | Immunology of the ageing kidney |
| Q90681140 | Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention |
| Q37713438 | Immunotherapy biomarkers 2016: overcoming the barriers. |
| Q93266237 | Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome? |
| Q99629123 | In vivo AAV delivery of glutathione reductase gene attenuates anti-aging gene klotho deficiency-induced kidney damage |
| Q93015569 | Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial |
| Q91968800 | Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation |
| Q64129464 | Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine |
| Q89081238 | Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients |
| Q28275005 | Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice |
| Q50114077 | Intermittent mTOR inhibition reverses kidney aging in old rats |
| Q49186484 | Interventions to restore appropriate immune function in the elderly |
| Q38846542 | Intracellular signalling pathways: targets to reverse immunosenescence |
| Q64244483 | Investigating the Role of Everolimus in mTOR Inhibition and Autophagy Promotion as a Potential Host-Directed Therapeutic Target in Infection |
| Q40140614 | Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination |
| Q38926261 | Key proteins and pathways that regulate lifespan |
| Q38882099 | Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease. |
| Q57469989 | Long-term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle-aged marmosets |
| Q37661792 | Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation |
| Q57286714 | Lysosome: The Metabolic Signaling Hub |
| Q44953337 | Mammalian Target of Rapamycin: A Target for (Lung) Diseases and Aging. |
| Q91946068 | Measuring biological aging in humans: A quest |
| Q39023427 | Mechanisms Underlying T Cell Immunosenescence: Aging and Cytomegalovirus Infection |
| Q51766026 | Melanoma Immunotherapy in the Elderly. |
| Q39494405 | Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse |
| Q36411111 | Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus) |
| Q36118020 | Microenvironment abnormalities and lymphomagenesis: Immunological aspects. |
| Q33665207 | Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy |
| Q40062364 | Multiple network-constrained regressions expand insights into influenza vaccination responses |
| Q35132669 | NIA's Intervention Testing Program at 10 years of age. |
| Q26775036 | Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection |
| Q38599715 | Natural products as probes in pharmaceutical research |
| Q57174537 | Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer's Disease |
| Q49849635 | New tricks from old dogs join the fight against ageing |
| Q91833159 | Next Generation Strategies for Geroprotection via mTORC1 Inhibition |
| Q38659532 | Novel strategies for anti-aging drug discovery |
| Q93118085 | Nutrition interventions for healthy ageing across the lifespan: a conference report |
| Q55031391 | Oral health in geroscience: animal models and the aging oral cavity. |
| Q40124899 | PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1. |
| Q28082761 | Paradoxical changes in innate immunity in aging: recent progress and new directions |
| Q91900415 | Partial Inhibition of mTORC1 in Aged Rats Counteracts the Decline in Muscle Mass and Reverses Molecular Signaling Associated with Sarcopenia |
| Q98779327 | Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop |
| Q37037799 | Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate |
| Q89669919 | Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome |
| Q40200529 | Physiologic Thymic Involution Underlies Age-Dependent Accumulation of Senescence-Associated CD4+ T Cells |
| Q92844503 | Physiology and pathology of T-cell aging |
| Q92422787 | Potentials of Host-Directed Therapies in Tuberculosis Management |
| Q36511303 | Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination |
| Q35563024 | Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage |
| Q39198154 | Prospects for combining targeted and conventional cancer therapy with immunotherapy |
| Q39571148 | Rapamycin Does Not Impede Survival or Induction of Antibody Responses to Primary and Heterosubtypic Influenza Infections in Mice |
| Q37000451 | Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes |
| Q90621894 | Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer |
| Q63508065 | Rapamycin and Alzheimer’s disease: Time for a clinical trial? |
| Q90510568 | Rapamycin for longevity: opinion article |
| Q37049112 | Rapamycin increases grip strength and attenuates age-related decline in maximal running distance in old low capacity runner rats |
| Q93334869 | Rapamycin rejuvenates oral health in aging mice |
| Q57475800 | Rapamycin rescues mitochondrial myopathy via coordinated activation of autophagy and lysosomal biogenesis |
| Q37514713 | Rapamycin rescues vascular, metabolic and learning deficits in apolipoprotein E4 transgenic mice with pre-symptomatic Alzheimer's disease |
| Q54963954 | Rapamycin treatment attenuates age-associated periodontitis in mice. |
| Q90431532 | Rapamycin, proliferation and geroconversion to senescence |
| Q37000488 | Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. |
| Q55013698 | Ras signaling in aging and metabolic regulation. |
| Q47819372 | Recent Advances in the Systems Biology of Aging |
| Q38639938 | Recent advances in the molecular design of synthetic vaccines |
| Q92859248 | Recent advances in understanding the mechanisms determining longevity |
| Q40077623 | Reduced dynamic range of antiviral innate immune responses in aging. |
| Q36260537 | Rejuvenating immunity: "anti-aging drug today" eight years later |
| Q38830314 | Resilience in Aging Mice |
| Q38964715 | Reversal of phenotypes of cellular senescence by pan-mTOR inhibition. |
| Q59132180 | Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions |
| Q41123306 | Role of Dendritic Cells in Inflammation and Loss of Tolerance in the Elderly |
| Q36733239 | SKN-1/Nrf, stress responses, and aging in Caenorhabditis elegans |
| Q64068942 | Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study |
| Q98776112 | Searching for the real function of mTOR signaling in the regulation of PD-L1 expression |
| Q51720692 | Senescence Can Be BETter without the SASP? |
| Q92019365 | Senescent cell clearance by the immune system: Emerging therapeutic opportunities |
| Q38609819 | Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents |
| Q47229701 | Short-term Low-Dose mTORC1 Inhibition in Aged Rats Counter-Regulates Age-Related Gene Changes and Blocks Age-Related Kidney Pathology |
| Q30377435 | Should we treat aging as a disease? The consequences and dangers of miscategorisation. |
| Q36356181 | Splenocytes derived from young WT mice prevent AD progression in APPswe/PSENldE9 transgenic mice |
| Q37322080 | Strategies and Challenges in Clinical Trials Targeting Human Aging |
| Q26768539 | T-Cell Immunity to Influenza in Older Adults: A Pathophysiological Framework for Development of More Effective Vaccines |
| Q94672372 | Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19 |
| Q92297313 | Targeting metabolism to regulate immune responses in autoimmunity and cancer |
| Q39312260 | The Clinical Potential of Senolytic Drugs |
| Q64256257 | The Cutting Edge: The Role of mTOR Signaling in Laminopathies |
| Q64052791 | The Interplay Between Age and Frailty in People Living With HIV: Results From an 11-Year Follow-up Observational Study |
| Q28276378 | The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging |
| Q36809947 | The Vital Role of Pathology in Improving Reproducibility and Translational Relevance of Aging Studies in Rodents |
| Q60358611 | The Way Forward: Translation |
| Q91937333 | The clock is ticking: the impact of ageing on T cell metabolism |
| Q38824857 | The dog aging project: translational geroscience in companion animals. |
| Q92332250 | The mystery of the ketogenic diet: benevolent pseudo-diabetes |
| Q64917514 | The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span. |
| Q95936711 | The quest to slow ageing through drug discovery |
| Q90246578 | The role of cellular senescence in ageing and endocrine disease |
| Q58613355 | The senescent cell epigenome |
| Q58771187 | The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation |
| Q47291933 | The twilight of immunity: emerging concepts in aging of the immune system |
| Q28069996 | Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks |
| Q52714820 | Transcriptional Profiling of Age-Associated Gene Expression Changes in Human Circulatory CD1c+ Myeloid Dendritic Cell Subset. |
| Q37201250 | Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. |
| Q38756902 | Translating the Science of Aging into Therapeutic Interventions |
| Q94528642 | Translational Geroscience: From invertebrate models to companion animal and human interventions |
| Q89587297 | Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment |
| Q90700616 | Translational geroscience: A new paradigm for 21st century medicine |
| Q48303439 | Translational strategies in aging and age-related disease |
| Q90854384 | Turning back time with emerging rejuvenation strategies |
| Q47159548 | Twenty-five years of mTOR: Uncovering the link from nutrients to growth. |
| Q39363654 | Unbalanced Growth, Senescence and Aging. |
| Q102334855 | Understanding immunosenescence and its impact on vaccination of older adults |
| Q61799981 | Using the drug-protein interactome to identify anti-ageing compounds for humans |
| Q47595817 | Vaccination choices for older people, looking beyond age specific approaches |
| Q94545406 | Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives |
| Q26770845 | When stem cells grow old: phenotypes and mechanisms of stem cell aging |
| Q35552767 | Why is aging conserved and what can we do about it? |
| Q47781510 | Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity |
| Q38747508 | mTOR Signaling in Growth, Metabolism, and Disease. |
| Q49486147 | mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review |
| Q91973686 | mTOR as a central regulator of lifespan and aging |
| Q42363764 | mTOR co-targeting strategies for head and neck cancer therapy |
| Q38590634 | mTOR in health and in sickness |
| Q90752811 | mTOR inhibitors for treatment of low-risk prostate cancer |
| Q91574084 | mTOR signaling mediates effects of common gamma-chain cytokines on T cell proliferation and exhaustion: implications for HIV-1 persistence and cure research |
| Q58795101 | mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases |
Search more.